Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class
medicines that meet significant unmet medical needs, today announced that additional data supporting IBSRELA (tenapanor) will be presented at the 2024 Digestive Disease Week Conference (DDW), to be
held May 18-21, 2024, in Washington, D.C. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults.
Title: Efficacy of Tenapanor in Patients with Irritable Bowel Syndrome With Constipation (IBS-C): A Posthoc Analysis of Patients With and Without Prior Use of Other IBS-C Prescription
Medications From the Phase 3 T3MPO-1 and T3MPO-2 Studies
Authors: Eric Shah, Brian Lacy, Yang Yang, Susan Edelstein, David Rosenbaum
Poster Number: Tu1658
Date/Time: May 21, 2024, from 12:30 PM to 1:30 PM EDT (UTC –4)
Title: Comparing the Efficacy of Tenapanor in Irritable Bowel Syndrome with Constipation in Hispanic vs Non-Hispanic Patients: A Posthoc Analysis of Patients in the Phase 3 T3MPO-1 and
T3MPO-2 Studies
Authors: Rosita Frazier, William Hasler, Yang Yang, Susan Edelstein, David Rosenbaum
Poster Number: Tu1663
Date/Time: May 21, 2024, from 12:30 PM to 1:30 PM EDT (UTC –4)
In addition to the poster presentations during DDW, Ardelyx is sponsoring a Product Theater titled: “Discover IBSRELA: a Different Mechanism of Action to Treat Adults With IBS-C: A Case-Based Discussion,” on May 19, 2024, from 2:30-3:15 PM EDT, where Brooks Cash, MD, will lead an engaging discussion about important clinical considerations for managing IBS-C in adult patients. The presentation will include interactive patient case studies, along with IBSRELA efficacy and safety data from the Phase 3 clinical trial program.
Lesen Sie auch
About IBSRELA (tenapanor)
IBSRELA (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for
the absorption of dietary sodium. By inhibiting NHE3 on the apical surface of the enterocytes, tenapanor reduces absorption of sodium from the small intestine and colon, thus retaining luminal
water content, which accelerates intestinal transit time and results in a softer stool consistency. IBSRELA has also been shown to reduce abdominal pain by decreasing visceral hypersensitivity and
by decreasing intestinal permeability in animal models. In a rat model of colonic hypersensitivity, tenapanor reduced visceral hyperalgesia and normalized colonic sensory neuronal excitability.